Compare Impinj Inc (PI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Impinj Inc trades at $189.45 (market cap $5.60B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Impinj Inc is more actively traded (39,355 versus 1,624,631). Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PI | SYRE | |
|---|---|---|
Market Cap | $5.60B | $7.35B |
Volume | 39,355 | 1,624,631 |
Sector | Technology | Health |
52-Week High | $241.91 | $108.92 |
52-Week Low | $91.34 | $22.18 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $5.74B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $183.26, down 3.56% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with EPS of $0.86 beating estimates, though it operates at a net loss margin of -7.26%. Recent news highlights CEO optimism about growth in RFID tracking markets and upcoming Q3 earnings.
Outlook remains mixed: analyst consensus is bullish (73% buy ratings) with a $178.83 price target, but high valuation multiples and persistent losses pose risks. Key catalysts include Q3 earnings and execution in retail and logistics segments, while competition and margin pressure are concerns.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
